Centene raises 2026 earnings floor as Marketplace enrollment falls 42% to 3.4 million
Centene's Marketplace membership fell to 3.4 million from 5.8 million, but the insurer lifted its 2026 adjusted EPS floor by 40 cents to more than $5.20 and said Medicare drove a better-than-expected quarter.

Centene's Affordable Care Act Marketplace business is shrinking fast, and the company says its earnings are recovering faster than it expected.
Centene Corp. said Oct. 27 that it raised its 2026 adjusted earnings guidance floor by 40 cents to more than $5.20 a share and its GAAP floor to more than $3.46, according to its earnings release. The St. Louis-based insurer's third-quarter health benefits ratio was 92.7%, unchanged from a year earlier. Centene said that was better than it expected, mainly because of Medicare, while Medicaid and the Marketplace performed as planned.
Why it matters: Centene ended September with 3.4 million Marketplace members, down from 5.8 million a year earlier, a drop of about 42%. Most of that came at the turn of the year: the company had 5.54 million Marketplace members at the end of 2025 and 3.58 million at the end of March, according to its quarterly membership table. At the same time its revenue mix is tilting toward Medicare: Medicare revenue rose 20% to $11.3 billion, while commercial revenue fell 21% to $8.7 billion.
Total revenue was $50.6 billion, and premium and service revenue rose 0.5% to $45.1 billion. Centene posted a GAAP loss of 14 cents a share and adjusted earnings of 58 cents. It lowered its full-year health benefits ratio range to 90.4% to 91.1%, which it said improves the midpoint by 15 basis points to 90.75%.
The flat quarterly ratio hides some movement underneath. Centene said a lower Marketplace ratio, reflecting improved pricing and risk adjustment transfers, and results in its Medicare Advantage and prescription drug plan businesses helped this year. The year-earlier quarter had been helped by a reduction in a premium deficiency reserve for Medicare Advantage; there was no such reserve this year, which Centene attributed to that business moving toward profitability.
Where the members went
Total Medicaid membership declined to 11.9 million from 12.7 million, while Medicaid revenue rose 4% to $24.0 billion. Membership in standalone Medicare prescription drug plans grew to 8.9 million from 8.0 million, and Medicare membership, which includes Medicare Advantage, fell to 954,400 from 1.01 million. Total at-risk membership was 25.7 million, down from 28.0 million.
Centene said premium growth came from higher drug plan premiums and enrollment, Marketplace and Medicaid rate increases meant to cover rising medical costs, Marketplace risk adjustment and state directed payments. Shrinking Marketplace and Medicaid enrollment offset part of that.
Elevance Health, which reported its third-quarter results six days earlier, also credited individual ACA plans, along with Medicare Advantage, for an improved benefit expense ratio.
Costs and cash
The adjusted selling, general and administrative expense ratio fell to 6.5% from 7.0%. Centene said that reflected cost management, lower Marketplace membership, which carries a higher expense ratio, and growth in the drug plan business, which carries a lower expense ratio. The unadjusted ratio rose to 7.2%, driven by severance and vendor costs from what the company called enterprise optimization. Severance and contract exit costs were $276 million in the quarter.
Centene said it has reduced debt by $1.1 billion since June 30, including fully redeeming its senior notes due 2027 in October. Total debt was $15.5 billion at quarter end, and $1.9 billion remained available under its senior note repurchase program as of Oct. 27. Cash used in operations was $3.7 billion in the quarter, which the company said reflected the timing of certain payments.
"Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated," Sarah London, chief executive, said in the release.
London said the company is focused on finishing 2026 strongly and building on that progress in 2027. The release did not give 2027 guidance.



